Precision Medicine
Cellular Immunotherapy, Precision Radiotherapy & Regenerative Stem Cell Therapy: Advanced Precision Medicine in China
Streamlined access, transparent pricing and specialized precision therapies across oncology, autoimmunity and regenerative care. SANA simplifies eligibility screening, hospital matching and medical record coordination into one unified treatment pathway.- Primary indication: Advanced hematologic malignancies
- Primary indication: Solid tumors requiring low-toxicity irradiation
- Primary indication: Autoimmune conditions & functional regenerative care
Technology 01
CAR-T Cell Therapy
A personalized autologous "living drug" manufactured from the patient's own T lymphocytes. Immune cells are collected via apheresis, genetically modified ex vivo to express chimeric antigen receptors (CARs) that recognize specific tumor surface antigens, expanded to therapeutic scale, then infused back into the patient to deliver targeted, sustained cancer cell destruction.Indications
Multiple Myeloma
- Relapsed/refractory multiple myeloma
- BCMA-directed CAR-T pathways after prior systemic therapy
Large B-cell Lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- High-grade B-cell lymphoma
- Large B-cell lymphoma transformed from follicular lymphoma
Acute Lymphoblastic Leukemia
- Relapsed/refractory B-cell acute lymphoblastic leukemia
- Pediatric, young adult, or adult pathways depending on protocol
Mantle Cell Lymphoma
- Relapsed/refractory mantle cell lymphoma
- Case review after prior treatment failure
Follicular Lymphoma
- Relapsed/refractory follicular lymphoma
- Usually considered after multiple prior lines of therapy
Chronic Lymphocytic Leukemia
- Selected chronic lymphocytic leukemia pathways
- Coverage depends on CAR-T product, protocol, and specialist review
Active Clinical Trials
>700 active (1,006+ historical)
~500 active (~549 historical)
Cell Turnaround Time
24-36 hours
2-4 weeks
Estimated Commercial Cost
$120,000 - $220,000
$373,000 - >$1,000,000
CAR-T Therapy at Shanghai Ruijin Hospital
Ruijin is SANA's key CAR-T pathway hospital in Shanghai, combining hematology strength, JCI-accredited Grade 3A resources, and international patient coordination.
Key Highlights
- Founded 1907, century-old prestigious hospital
- Leukemia "Shanghai Protocol" with 95% cure rate
- Proton Therapy Center
- 16-language interpreter support
- 21+ international insurer direct billing
- Affiliated with Shanghai Jiao Tong University
Technology 02
Proton Therapy
Unlike conventional photon (X-ray) radiation that deposits energy along the entire beam path, proton therapy uses positively charged proton beams with a unique Bragg peak physical property. Nearly all radiation energy is delivered at the exact depth of the tumor, with minimal exit dose and drastically reduced damage to adjacent healthy organs — making it a highly targeted, low-toxicity physical treatment option.Estimated Cost (Full Course)
$30,000 - $80,000
$100,000 - $200,000+
Proton Centers
~8-10 operational, rapidly expanding
~45+ operational
Treatment Initiation
1-2 weeks from consultation
3-8 weeks from consultation
Technology Generation
Latest Varian ProBeam 360 with IMPT + CBCT
Mix of older and newer systems
Indications
Head & Neck
- Nasopharyngeal & oropharyngeal tumors
- Orbital & skull base tumors
- Re-irradiation of prior radiation field
Chest
- Non-small cell lung cancer
- Esophageal carcinoma
- Thymoma & mesothelioma
- Post-surgical bilateral N2 lesions
Gastrointestinal
- Hepatocellular carcinoma
- Intrahepatic cholangiocarcinoma (ICC)
- Solitary liver metastasis (colorectal)
Urogenital
- Early-stage & locally advanced prostate cancer
- Solitary pelvic lymph node metastasis
CNS
- Meningioma & sellar tumors
- Low-grade gliomas
- Craniospinal irradiation
Breast & Gynecological
- Accelerated Partial Breast Irradiation (APBI)
Pediatric
- Astrocytoma, medulloblastoma, ependymoma
- Ewing's sarcoma, osteosarcoma
- Retinoblastoma, rhabdomyosarcoma
Sarcoma & Lymphoma
- Mediastinal & paraspinal lymphoma
- Total brain & spinal cord irradiation
Proton Therapy at Guangzhou Concord Cancer Center
Guangzhou Concord is SANA's proton therapy pathway hospital, built around next-generation radiation equipment and specialized oncology care workflows.
Key Highlights
- First Varian ProBeam 360° proton system in South China
Official MD Anderson Cancer Center collaboration
- Mayo Clinic strategic partnership
- Four 360° rotating gantry treatment rooms
- IMPT with pencil-beam scanning + CBCT image guidance
- Da Vinci robot, PET-MRI, PET-CT, TrueBeam accelerators
- NCCN + MD Anderson radiotherapy standards + JCI
- International-standard private suites + Smart Hospital
World-Leading Medical Equipment
- Varian ProBeam Proton System - First in South China, 4 gantry rooms, IMPT + IGPT
- Da Vinci Surgical Robot - Precision minimally invasive surgery
- PET-MRI - Next-gen molecular imaging
- PET-CT - High-precision tumor metabolic imaging
- TrueBeam LINAC - 4 rooms, world's most advanced new-gen linear accelerator
- Digital Class-100 laminar flow operating rooms
Technology 03
Stem Cell Therapy (Regenerative Medicine)
This branch of regenerative medicine leverages the self-renewal, multi-lineage differentiation and paracrine signaling capabilities of human umbilical cord mesenchymal stem cells (hUC-MSCs) to repair damaged tissue, modulate local microenvironments and support functional recovery.On this page, SANA presents ED and RA separately so eligibility, preparation, and expected clinical review can be understood clearly.
hUC-MSC for Erectile Dysfunction (ED)
Delivered via intracavernous injection, hUC-MSCs exert paracrine effects that promote angiogenesis, neurorestoration and antifibrotic remodeling within the corpus cavernosum, addressing the underlying vascular, neural and fibrotic tissue damage that contributes to erectile dysfunction.
Clinical challenge
- PDE5 inhibitors are common first-line therapy, but they are symptom-oriented and may be unsuitable for patients using nitrate medications.
- Device therapy, intracavernosal medication injection, or surgery can create practical burden, variable acceptance, and higher perceived treatment friction.
- Patients with diabetes, vascular risk factors, or nerve injury may require deeper specialist assessment before a regenerative pathway is considered.
Regenerative rationale
- Local hUC-MSC delivery is reviewed for paracrine effects that may support angiogenesis, neurorestoration, and smooth-muscle microenvironment repair.
- The pathway is framed around cavernous tissue remodeling, antifibrotic signaling, and recovery of endothelial and neural function.
- Clinical discussion should remain eligibility-based, with outcomes assessed through specialist review rather than generalized promises.
Pre-review materials
- IIEF-5 or EHS scoring, ED duration, prior PDE5 inhibitor response, and current medication list
- Metabolic and vascular risk review, including diabetes status, blood pressure, lipid profile, testosterone when relevant, and PSA screening
- Specialist tests may include nocturnal erection monitoring, penile Doppler ultrasound, and broader urology evaluation
hUC-MSC for Rheumatoid Arthritis (RA)
hUC-MSCs exert broad immunomodulatory effects to suppress overactive autoimmune responses in RA patients, while supporting the repair of damaged articular and synovial tissue in affected joints.
Clinical challenge
- Conventional RA treatment can reduce inflammation, but refractory disease and medication intolerance remain common clinical problems.
- Long-term steroid or immune-suppressive regimens may be limited by infection risk, metabolic effects, pregnancy or breastfeeding restrictions, and other adverse events.
- RA care needs to address immune imbalance and joint structural injury, not only short-term pain or swelling.
Regenerative rationale
- hUC-MSCs may help rebalance innate and adaptive immune activity, including macrophage M1/M2 and Th17/Treg pathways.
- Paracrine signaling may reduce inflammatory mediators such as CRP, IL-6, and TNF-alpha in selected clinical contexts.
- The repair-oriented pathway focuses on supporting cartilage and bone microenvironments while inhibiting excessive osteoclast activity.
Pre-review materials
- Confirmed RA diagnosis, recent treatment history, and current medication plan
- Inflammatory and autoimmune markers such as CRP, ESR, rheumatoid factor, anti-CCP, IL-6, and TNF-alpha when available
- Safety screening, infection screening, tumor-marker review, cardiopulmonary evaluation, and relevant joint imaging
